Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498085 | 0.77 | — | — | |
| SCHEMBL497923 | 0.71 | — | — | |
| SCHEMBL4919306 | 0.69 | — | — | |
| SCHEMBL4915970 | 0.68 | — | — | |
| SCHEMBL6051704 | 0.65 | — | — | |
| SCHEMBL4921831 | 0.64 | — | — | |
| SCHEMBL16689074 | 0.62 | CA1 (0.38) | CA1CA9 | |
| SCHEMBL16689076 | 0.62 | CA1 (0.38) | CA1CA9 | |
| SCHEMBL27672482 | 0.62 | CA1 (0.38) | CA1CA9 | |
| Butyrolactone SCHEMBL1271043 | 0.58 | CA1 (0.82) | CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8852727-B2 | Ink composition, image forming method, and printed matter | FUJIFILM CORPORATION (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2664658-A1 | INK COMPOSITION, IMAGE FORMING METHOD, AND PRINT | FUJIFILM Corporation (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-20130295344-A1 | INK COMPOSITION, IMAGE FORMING METHOD, AND PRINTED MATTER | FUJIFILM CORPORATION (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2492322-A1 | Ink composition, image forming method, and printed material | Fujifilm Corporation (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120213978-A1 | INK COMPOSITION, IMAGE FORMING METHOD, AND PRINTED MATERIAL | FUJIFILM CORPORATION (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2049535-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090088419-A1 | PYRIDYL ACETIC ACID COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | US | disclosed |
| CN-101166725-A | Pyridylacetic acid compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-04-23 | — | — | CN | disclosed |
| WO-2008016184-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| US-20070259927-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2007-11-08 | — | — | US | disclosed |
| EP-1851202-A1 | PYRIDYL ACETIC ACID COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1782832-A1 | REMEDY FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2006090915-A1 | PYRIDYL ACETIC ACID COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-31 | — | — | WO | disclosed |
| EP-1678138-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042488-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259927-A1 | Remedy for Diabetes | IAPP, DPP4, PNLIP | CA1 397/4885CA9 189/4885 |
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | XDH, F7, CYP4X1 | CA1 63/4885CA9 35/4885 |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | CA1 1583/4885CA9 1168/4885 |
| US-20090088419-A1 | PYRIDYL ACETIC ACID COMPOUNDS | DPP4, GPR119, DPP3 | CA1 371/4885CA9 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.